Document Detail


Adult Ewing Sarcoma: Survival and Local Control Outcomes in 36 Patients With Metastatic Disease.
MedLine Citation:
PMID:  23388557     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES:: To assess the clinical features and outcomes in adult patients with metastatic Ewing sarcoma (ES). METHODS:: The records of 36 ES patients with metastatic disease ≥18 years seen from 1977 to 2007 at the Mayo Clinic were studied retrospectively. Factors relevant to prognosis, survival, and local control (LC) were analyzed. RESULTS:: The 4-year overall survival (OS) and event-free survival (EFS) rates were 20% and 11%, respectively. Patients treated from 1993 to 2007 had significantly improved outcomes compared with those treated from 1977 to 1992: 4-year OS and EFS of 31% and 16%, respectively, versus 0% (P=0.01). Primary tumor (P=0.005 and 0.04) and metastatic sites (P=0.05) were independent EFS prognostic factors. Four patients (11%) received surgery, 18 (50%) radiation therapy (RT), 4 (11%) surgery+radiation therapy (S+RT), and 10 (28%) received no LC. The 4-year EFS rates were 0% for surgery, 21% for RT, 0% for S+RT, and 0% for no LC (P=0.0001). OS in patients who received vincristine, doxorubicin, and cyclophosphamide alternating with ifosphamide and etoposide (VDC/IE) chemotherapy was improved (P=0.04). Relapses were documented in 18 patients (excluding patients who received no LC). In total, 44% of patients had all of their metastatic site(s) treated. Patients who received treatment to all extrapulmonary metastases had significantly improved outcomes compared with those who did not receive treatment to all sites: 4-year OS and EFS of 33% and 11%, respectively, versus 0% (P=0.04 and 0.02). CONCLUSIONS:: Our results suggest outcomes for adult patients with metastatic ES are similar to pediatric cohorts in the modern era. VDC/IE chemotherapy and treatment to all metastatic lesions is associated with improved outcomes.
Authors:
Safia K Ahmed; Steven I Robinson; Scott H Okuno; Peter S Rose; Nadia N Issa Laack
Related Documents :
24533527 - Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient ma...
24931507 - Japan clinical oncology group prognostic index and characterization of long-term surviv...
23242847 - Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in...
15284587 - Persistent human parvovirus b19 infection in children under maintenance chemotherapy fo...
21088487 - Fasting and differential chemotherapy protection in patients.
2767107 - Acral erythema and systemic toxicity related to cha induction therapy in acute myeloid ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-5
Journal Detail:
Title:  American journal of clinical oncology     Volume:  -     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
*Mayo Medical School Divisions of †Oncology ‡Orthopedic Surgery §Radiation Oncology, Mayo Clinic, Rochester, MN.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of Dynamic MRI and Clinical Assessment in Predicting Histologic Response to Neoadjuvant Chemoth...
Next Document:  Treatment-related Acute Esophagitis For Patients With Locoregionally Advanced Non-Small Cell Lung Ca...